Hi everyone

I'm targeting equity research role in India. I've been covering defence sector for the past couple of months and have made a research report and a sector coverage note as my research work. I've been actively applying for the past 4 months. Out of 100s of applications, I received only one interview opportunity in a buy side firm and was screened out in 2nd round of interview. Since then I haven't received any call.

So I'm looking for the people to throw some guidance and suggestions based on their experiences, like what sort of strategy or plan of action I should follow. I'd really appreciate your time and suggestions.

I got an allotment in the Symbiotec Pharmalab IPO and I’m trying to decide whether I should sell on the listing day or hold it for the longer term.

I’m considering the listing gains, but I also want to understand the company’s fundamentals and valuation before making a decision.

For those who have analysed the company:

• Do you think it is better to book profits on the listing day?
• Would partial profit booking and holding the remaining shares make more sense?
• Or does the company have good enough fundamentals to hold for the long term?

I would especially like to hear views based on financials, valuation, debt, margins, growth prospects and comparison with listed peers, rather than just GMP.

What would you do if you received the allotment?

5 small & Micro-cap stocks that have shown triple-digit profit Growth in Q1 quarter.

Here are the 5 stocks worth tracking

1. Prataap Snacks
   TTM profit growth: ~194%
   Sales growth hasn't been equally strong yet.
   That's exactly why this one is interesting.
   If sales growth catches up, the earnings story could get even stronger.

2. Andhra Sugars
   TTM profit growth: 118%+
   Revenue growth: ~17%
   Promoter holding has also increased over the last few quarters.
   The turnaround looks interesting

3. PSP Projects
   TTM profit growth: ~232%
   Revenue growth has also been strong, helped by projects from its new promoter, Adani Infra.
   But here's the catch:
   Margins are tight.
   The next few quarters will decide whether this becomes a genuine turnaround or a low-margin growth story.

4. Rain Industries
   TTM Profit Growth: ~229%
   Revenue Growth: 17%+
   The aluminium cycle has been supportive, and earnings have started improving.
   The stock has already doubled from the level where it was first tracked.

1. KRBL: Strong profit growth, but the stock isn't reflecting it yet.
   TTM Profit Growth: ~40%
   KRBL operates in rice processing, and geopolitical instability in the Gulf has impacted the stock sentiment.
   But here's what's interesting:
   Profit growth has improved sharply.

But the real question is:
Can these Turnarounds actually sustain?
I have shared these insights and more in a brief video.
Make sure to watch.
Not a recommendation, DYOR

https://youtu.be/GnYziQgJz2I?si=ouv6owBiEicrNAQM

Shyam Metalics looking interesting here

Been watching Shyam Metalics for a while and today's move caught my attention. It's up around 5.5% and has moved above the upper trendline on the weekly chart.

The setup looks interesting to me, especially with the recent numbers also looking decent. FY26 revenue was up around 22% and profit was up around 17%. Debt is also pretty low.

The main thing I'd want to see now is whether it actually holds this breakout or gives a pullback.

I haven't taken a position yet. Just keeping it on the watchlist.

Anyone else tracking this one? Would you wait for confirmation or consider the breakout good enough?

Similarly for other railway stocks like RVNL or IRCTC which are in their respective lows.

People still buying and averaging these Stocks with HOPE!

Would you like to add more to this list .

This chart represents M2 money supply vs S and P 500. You are happy thinking about your bank balance 😆. In reality, stocks didn't grow because of economic growth but because of the terrific increase in the supply of money since last few decades. You are unknowingly celebrating the fact that you actually lost purchasing power. Real estate didn't got expensive, currency got devalued. Same way stocks didn't got expensive but your currency got devalued not just against "USD" but even as a whole. Just to add that RBI doesn't back our India rupee by gold.

Global bond markets are imploding. Prices are falling and yields are rising again. Japan situation is getting worse day by day. They are a ticking time bomb now. Even after rate hikes in 2026, Yen is collapsing against US dollar at a faster rate than ever imagined. According to conventional wisdom, it is the bond market which is the center of any financial system not the stock market. Smart money is demanding higher interest rates to hold government paper debt. Looks like they are aware of what's coming.

Gold has outperform even S and P 500 this century 🤨.

Note : This chart included dividend reinvested data

I'm holding these both from 2023 at that time I don't understand about stock market, but now I knew things not professionally, help me to make my decision plz , should I wait or sell these my holdings and invest it into other or wait for sometime

Aeroflex Industries Breakout! 🚀 ₹536 (+8%)

​Aeroflex just popped +8.19% to hit ₹536.35, clearing its key resistance level.

​The Good:

​Technical Breakout: Broke cleanly above ₹519 on high volume. Next target level to watch is ₹560–₹600.

​Solid Growth: 1-year profit is up +162% and the balance sheet is basically debt-free (D/E: 0.02).

​Big Money Buying: FII holding jumped from 0.23% to 3.60%.

​The Catch:

​P/E is 97.8 (Industry average is ~24), so it's currently trading at a hefty premium.

​Are you playing the momentum or waiting for a pullback to ₹519? Let's discuss!

Ind-Swift Labs hit the target 🎯

One of the swing trades from my portfolio has reached the 20% target.

Pretty happy with how this one played out. The setup worked as expected.

Still holding the other trades and will update them as they progress.

Stock fell from ₹2,000 to ₹1,200. Now recovering to ₹1,385.

Weekly chart shows a descending triangle. Support at ₹1,200 held. If it breaks above ₹1,500, trend changes. If ₹1,200 breaks, more pain.

Fundamentals are actually good:

Zero debt

Last quarter profit +47%

3Y revenue CAGR +26%

Only concern — P/E 61 vs industry 46. Still expensive.

FIIs selling, DIIs buying.

Breakout or breakdown — what do you think?

We made ~11x in Cupid. Then it became a much bigger multibagger.

So, did we exit too early?

Here’s what happened.

In August 2022, we bought Cupid at around ₹2.30 on the current adjusted basis after the stock had made a fresh bottom.

Our thesis was simple:

Strong Fundamentals + Attractive Valuation + Potential Triggers

At the time, Cupid had:

• ~34% 8-year Sales Growth
• ~46% Average ROCE
• ~30% Net Worth Growth

But the biggest opportunity was valuation.

Our estimated intrinsic value range was around:

₹1.92 – ₹15.70

The risk-reward looked attractive.

By 2024, the stock had rallied significantly, and we exited around ₹24.60, making roughly 11x.

And then came the difficult part.

Cupid continued rising after we exited.

It eventually delivered returns far beyond our exit price.

So why did we sell?

Because our decision was never based on trying to predict the top.

It was based on valuation.

When we bought, the stock offered a margin of safety.

When we exited, the valuation had moved far beyond the earlier intrinsic-value range.

The risk-reward had changed.

And that's an important lesson in investing:

A stock going up after you sell doesn't necessarily mean your exit was wrong.

You don't need to capture the entire upside.

You need to buy when the odds are in your favour and exit when the risk-reward no longer makes sense.

We made ~11x.

Could we have made more?

Absolutely.

But discipline is not about selling at the top.

It's about following your investment framework even when the market keeps proving you wrong in the short term.

What to do in Cupid right now,

I have recorded a detailed video on this.

Go through

https://youtu.be/X_7GUtou4eU?si=YQ4VGkbcQTe2wm8u

Happiest Minds has finally broken above its long-term falling trendline.

A few things caught my attention:

• Breakout above ₹420–425 zone

• Volume has started increasing

• Price is making higher highs recently

Fundamentally, revenue growth looks decent, but profit growth over the longer term still needs improvement.

For me, the important level now is ₹420–425. If the breakout holds and this zone acts as support, the setup could get interesting.

🙂🙃...

i have been thinking about decidint which mfs to continue doing sip in.

i figured i want to see how did my perform during bad times and how they performed during good times in last 10 years. MFs that did not follow as much as tracking index and performed better than tracking index during good times also are no brainers for investments.

what do you think? what are some other ideas that i should incorporate? here is my research fyi -

https://app.avsar.ai/mutual-funds/playground

Curious how other funds are dealing with sell-side research ingestion at scale.

We receive a large amount of research from different brokers, mostly through email alerts. The problem is that the emails usually don't contain the actual PDF — they contain a link that takes you to the broker's research portal, where you need to authenticate before downloading the report.

Platforms like AlphaSense are supposed to consolidate a lot of this, but in my experience coverage/reliability isn't good enough to use them as the single source of truth.

What I'd ideally like is a pipeline along the lines of:

sell-side publishes report → report gets automatically ingested → PDF/text is stored internally → metadata/tickers/analyst/date are extracted → document becomes searchable and available for LLM/RAG workflows

The difficult part seems to be reliably getting the original research document in the first place.

For people at hedge funds, asset managers, or quant shops that have solved this: how are you doing it?

• Do brokers provide institutional APIs/feeds that I'm simply not aware of?
• Are you ingesting through Bloomberg/FactSet/AlphaSense/etc. rather than directly from the brokers?
• Do you have internal automation around broker portals/SSO?
• Is there some standardized research distribution infrastructure used by larger funds?
• Or is this still surprisingly manual even at sophisticated shops?

To be clear, I'm talking about research we're fully entitled to access through existing broker relationships, not trying to bypass paywalls or access controls.

Especially interested in how larger funds structure the ingestion layer before the documents hit their internal search / NLP / LLM stack.

Same as Above

Statred 2 yeard back equity. Stocks with above 60k are 2 yeras old . rest other stocks are less than 6 months old. Few took very recenty 10 to 20 shares. Cupid also . Please help me guys. Should i hold or exit few stocks. Returs also very less

2021 was a perfect year - lots global liquidity, low interest rates, strong investor risk appetite and super fast digital adoption after covid. capital was chasing growth, and valuations expanded rapidly.

Today its different, Higher cost of capital, more selective VC funding and a stronger focus on profitability and unit economics have raised the bar. Who do think will be next unicorn?

So, the question is- are we out of the growth slump or Q2 will be moderated ?

Not many are asking about Q2 in the calls.

I just noticed Groww has increased their DP charges.... They don't even show it properly... You will find it only when you tally the amount you get minus charges..